Loading organizations...
Gangwal Chemicals specializes in the manufacturing of pharmaceutical ingredients and excipients. The company develops and produces active pharmaceutical ingredients (APIs) and formulates specialized excipient premixes, including directly compressible granulated excipients. This technical focus enables the production of high-quality raw materials crucial for the pharmaceutical industry, supporting the formulation of various medicinal products.
Founded in 1987 by Anil Jain, Gangwal Chemicals originated from an insight into the critical need for reliable and quality pharmaceutical raw materials within the Indian market. Jain established the enterprise to address this gap, subsequently expanding its portfolio to encompass a broader range of solutions for pharmaceutical manufacturers. His vision laid the groundwork for what evolved into a significant presence in the industry.
Gangwal Chemicals primarily serves pharmaceutical and nutraceutical manufacturers globally, providing essential components for their formulations. The company's long-term vision centers on advancing healthcare through consistent innovation and the provision of high-standard ingredients, aiming to be a trusted strategic partner for pharmaceutical brands seeking precision and quality in their product development.
Gangwal has 1 tracked investment across 1 company. The latest tracked deal is $497.0M Debt / Series B in Scalapay in February 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 23, 2022 | Scalapay | $497.0M Debt / Series B | Tencent Holdings, Willoughby Capital | Deimos, Fasanara Capital, Moore Capital, Tiger Global |